This study demonstrates the clinical efficacy of Manasamitra Vataka and Shirodhara (Ayurvedic treatments) over clonazepam in preserving slow wave sleep and promoting sleep quality in patients of generalized anxiety disorder (GAD) with co-morbid generalized social phobia. Whole night polysomnography was carried out to assess the sleep architecture and spindledelta dynamics. The study highlights the sleep promoting and preserving nature of Manasamitra Vataka and Shirodhara in GAD patients with co-morbid generalized social phobia. Ayurvedic treatments were helpful in improving the subjective quality of sleep and preserve sleep organization. Further studies are needed to confirm the potential of Ayurvedic interventions as a treatment of choice in the management of anxiety disorders.
Introduction
GENERALIZED anxiety disorder (GAD) is a common disabling chronic disorder characterized by excessive worry accompanied with a wide range of physical symptoms like sweating, palpitation, etc. Social phobia (SP) is one of the most frequent co-morbidity of GAD, characterized by irrational fear of public humiliation or embarrassment.
Sleep disturbances are common manifestation of major depressive and anxiety disorders 1, 2 . Relatively little research has been focused on sleep disturbances in anxiety disorders compared to affective disorders. Disturbances in sleep such as trouble in falling asleep or staying asleep, increased daytime fatigue, decreased sleep efficiency, increased sleep latencies, intermittent awakenings, reduced slow wave sleep (SWS) and rapid eye movement (REM) sleep states have been reported in patients with GAD 1, 3, 4 . Though sleep disturbances are reported in patients with social phobias, polysomnographic studies to ascertain the sleep architecture among GAD patients with co-morbid social phobia are scanty. Additionally, conventional anxiolytic agents such as clonazepam have been reported to affect sleep quality. Shortterm use of benzodiazepines helps improve the sleep quality, sleep duration and efficiency, but alters the sleep architecture 5 . Long-term treatment has many deleterious effects on sleep 6 . Serotonin-norepinephrine reuptake inhibitors (SNRI) and selective serotonin reuptake inhibitors (SSRI) on the other hand, suppress REM sleep and increase nocturnal arousals 7 . Considering such side effects of these agents on sleep, newer treatment strategies are encouraged in the management of anxiety disorders. An alternative system of medicine such as Ayurveda is one such possibility and anxiety was found to be the strongest predictor (odds ratio 3 : 1; 95% confidence interval, 1.6-6.0) for patients to use this system of medicine 8 . Manasamitra Vataka 9 and Shirodhara therapy (dripping of medicated oil over the forehead) are the most widely used Ayurvedic treatments for GAD. We have demonstrated the clinical effectiveness of Manasamitra Vataka and Shirodhara therapy over clonazepam in the management of GAD with co-morbid generalized social phobia, as these treatments were found to have potent anxiolytic properties 10 . The present study investigates the effectiveness of these treatments on sleep organization in GAD patients with co-morbid generalized social phobia.
Methodology
This was an open label, randomized, controlled, parallelgroup study. Patients attending the psychiatry outpatient department of psychiatry at the National Institute for Mental Health and Neurosciences (NIMHANS), Bengaluru were recruited for the study. The methodology used is described in a previous publication 10 ; however, important components are described here.
Patients
Right-handed patients (n = 72), between 20 and 55 years of age, diagnosed with GAD and co-morbid generalized social phobia according to the DSM-IV-TR criteria by a psychiatrist and meeting Hamilton anxiety rating scale (HARS) >18 (ref. 11), were recruited from the psychiatric outpatient department at NIMHANS. Patients with significant depression (Beck depression inventory scores >17), any other AXIS I and medical disorders, or on any psychotropic drugs within four weeks prior to the study were excluded. Patients with substance abuse, as well as pregnant and lactating females were excluded. Patients were explained about the nature and design of the study and informed consent was obtained. The study was initiated after obtaining approval from the Institute ethics committee.
Treatment
Patients were randomized (blocked randomization) into one of the three groups; Group-I, (n = 24) received tablet Manasamitra Vataka (100 mg, twice daily, for 30 days according to the literature) 9 , group-II (n = 24) received Shirodhara 10 with Brahmi tailam (oil-based extract of Bacopa monniera) in the morning 12 for the first seven days in addition to tablet Manasamitra Vataka as mentioned for group-I. Manasamitra Vataka is classical drug 9 ; details of its compound formulation has been provided in the earlier study 10 . Manasamitra Vataka tablets were procured from the Central Research Institute (Ayurveda), Cheruthuruthy, a unit of the Central Council for Research in Ayurvedic Sciences, Department of AYUSH, Ministry of Health and Family Welfare, Government of India. Group-III (n = 24) received clonazepam tablet (0.25 mg in the morning and 0.50 mg at night) for 30 days. Medications were administered in the morning and 1 h prior to the habitual sleep time.
Whole night polysomnography and sleep architecture assessment
Subjects were asked to maintain a sleep diary and abstain from alcohol, caffeine and naps two weeks prior to the study until completion of the treatment. In addition, whole-night polysomnographic (PSG) recordings were made in a semi-sound proof recording chamber (sleep cabin) under video-monitored supervision in a standard sleep laboratory setting during the patients' habitual sleep timings. We carried out whole-night PSG for two consecutive nights, both before as well as following the treatment intervention. In both cases, the first night's recording was for habituation to the laboratory settings and the second night's recording was for sleep architecture assessments. PSG was recorded according to the method described by the Rechtshaffen and Kales 13 . EEG was recorded using disc electrodes placed bilaterally in frontal (F3, F4), central (CZ), and occipital (O1, O2) positions based on the 10-20 system recording of EEG introduced by Jasper 14 . EOG electrodes were placed on both canthi and EMG was recorded from the chin muscles. EEG and EOG were recorded with a time constant of 0.3 sec and a sensitivity of 5 V/mm and low pass filter 70 Hz, whereas EMG had a time constant of 1.0 sec and sensitivity of 5 V/mm and low pass filter 70 Hz respectively, using a 32-channel digital Neurofax EEG instrument (Neurofax EEG 2110, Nihon Kohden, Japan). The electrical impedance was kept below 3 K. The monopolar derivation of EEG and EOG was utilized for assessment of the sleep stages using Polysmith software (version 1.7.8R16H; Nihon Kohden, Japan). Epoch by epoch visual scoring was done manually by a trained scorer blind to the study. Sleep architecture and assessment of sleep variables such as sleep efficiency, sleep onset latency, total sleep time, duration of each sleep stages, etc. have been assessed according to Rechtshaffen and Kales classification of sleep stages 13 .
Assessment of spindle-delta dynamics
A sub-sample of the PSG data acquired from group-I and group-III patients (group-I: n = 9; group-III: n = 10; agematched; data taken both before and after treatment) were subjected to spindle-delta dynamics analysis. First, the EEG data were converted to 'EDF' format (European Data Format; using EDF browser v1.54 software) and imported into EEGLAB toolbox within MATLAB software, where further analysis was carried out. The sleep EEG data were pre-processed using FIR-based band-pass filtering (0.5-35 Hz) and notch filter (50 Hz). Two time-frequency analysis strategies were undertaken on Cz channel of the pre-processed sleep EEG data; a conventional timefrequency approach based on 'Hilbert transform' and another approach based on 'Neuroloopgain' (Polyman v1.15.3 software). Cz channel (referenced to averaged ear lobe electrodes) was chosen as it is a recommended site to observe both spindle and delta oscillations 13 . For the Hilbert transform approach 15 , the channel data were first band-pass filtered to 11-16 Hz (for sleep spindles) or 0.5-4 Hz (for delta waves), and then Hilbert transform applied to extract the instantaneous magnitude (amplitude). The amplitude time series was then squared and further smoothened (using 0.01 Hz low-pass FIR filtering) to represent the spindle or delta dynamics across the whole night.
Neuroloopgain analysis was done using the Neuroloopgain plugin of Polyman software. Neuroloopgain is a measure of micro-continuity of sleep-related delta and spindle oscillations, and is independent of the amplitude of EEG rhythms 16 . In brief, Neuroloopgain or microcontinuity analysis uses a resonance filter (which enhances the frequency band that needs to be passed) to constantly track the rhythmic EEG component (spindle or delta oscillation) between consecutive EEG samples. The filter's response is used to predict the rhythm that is expected to continue to the next (20 ms later) EEG sample, and the fraction of predicted signal that repeats is expressed as micro-continuity percentage (0-100) per second of sleep EEG data. This measure relies on the physiological model that gain in sleep neural network modulates the gain in spindle or delta oscillatory feedback loops.
We used median power, cumulative power (integrated over whole sleep), median Neuroloopgain and cumulative Neuroloopgain (integrated over whole sleep) as measures of spindle-delta dynamics across whole-night sleep data, irrespective of sleep stages. Cumulative parameters were computed as sum of power or Neuroloopgain values above the median value for each subject.
Statistical methods
Statistical analysis was carried out using SPSS version 15.0. Homogeneity of data across the groups was evaluated by  2 test. Comparison of groups across different time points was done using repeated measures ANOVA with Bonferroni post-hoc test. Values are reported as mean  1 standard deviation (SD). All tests were considered statistically significant P < 0.05. By considering the 16 variables of polysomnography, adjustment to multiple corrections was done. P < 0.003 was considered to be significant. All the time-frequency measures for sleep spindles and delta waves were log-transformed before statistical analysis using the non-parametric Wilcoxonsigned rank test with significance set at P < 0.006 (after Bonferroni's correction for eight measurements per group).
Results

Patient profile
Out of 72 patients recruited for the study, seven (two each from group-I and group-II, and three from group-III) dropped out due to personal problems unrelated to the study. Some patients (two patients each from group-I and group II) reported with mild abdominal colic which subsided without any intervention and six patients from group-III reported daytime sleepiness during the first week of meditation without affecting their daytime functioning. The mean age, gender, height, weight, body mass index, duration, severity of illness and history of sleep disturbances were comparable in all the three groups 10 ( Table 1) . Baseline values of sleep architecture (Table 2) were also comparable between groups.
Sleep quality assessment
Details of sleep quality (especially time of waking, time of getting out of bed, waking up refreshed or tired, time of going to bed, time of falling asleep, number of night awakenings, duration of night awakenings and factors affecting sleep) were obtained from the sleep diary maintained by the patients. Table 1 provides the sleep disturbances ascertained from the sleep diary. All the interventions brought significant improvement in sleep quality. Effect of interventions was comparable between groups, except the duration of night awakenings (P = 0.005), which was improved in group-II (P = 0.005) and group-III (P = 0.006) compared to group-I (Table 3) .
Sleep architecture assessment
Most of the sleep variables such as sleep efficiency index, sleep duration, REM duration, sleep onset latency, REM onset latency, total wake duration, micro arousal index and sleep cycle were comparable between groups ( Table 2 ). The non-rapid eye movement (NREM) state [expressed as % (F (1, 62) = 38.063, P < 0.001) and in minutes (F (1, 62) = 32.088, P < 0.001)] showed significant changes among groups with time as within group factor; however group-III showed significant reduction compared to group-I (Table 2 ; Figures 1 and 2 ).
NREM stage 2 (%)
Repeated measure ANOVA with time as within subject factor and groups as between subject factor showed a significant effect of time (F(1, 62) = 24.994, P < 0.001). There was also a significant effect of group (F(2, 62) = 11.857, P < 0.001). Post-hoc tests revealed significant increase in group-III compared to group-I (P = 0.016) and group-II (P < 0.001) after treatment. Group  time interaction was significant (F(2, 62) = 20.972, P < 0.001). Post-hoc analysis showed that post-treatment NREM stage (S2) (%) in group-III was significantly increased compared to group-I and group-II (P < 0.001; Table 2 and Figures 1 and 2) . . Level of significance is *P < 0.05, **P < 0.01, ***P < 0.001.
NREM slow wave sleep
Repeated measure ANOVA with time as within subject factor and groups as between subject factor showed a significant effect of time (F(1,62) = 17.710, P < 0.001). There was also a significant effect of group (F(2,62) = 6.368, P = 0.003). Post-hoc tests showed significant decrease in group-III compared to group-I (P = 0.004) and group-II (P = 0.020). Group  time interaction was significant (F(2,62) = 31.138, P < 0.001). Post-hoc analysis showed that post-treatment SWS in group-III was significantly decreased compared to group-I and group-II (P < 0.001; Table 2 and Figures 2 and 3) . Major significant changes were observed in NREM S2% and for SWS between groups. Post-treatment increase in NREM S2% (P < 0.001) and decrease in SWS (P < 0.001) was observed in group-III compared to group-II and group-I. The REM sleep states were not altered in patients and remained the same following treatment in all three groups. The representative hypnograms (Figure 2 ) highlight the changes brought about by the interventions.
Spindle-delta dynamics across the whole night
Group I showed no significant difference in any of the spindle or delta dynamics parameters between pre-and post-treatment (Table 4 and Figure 4 ). Whereas group-III showed significant reduction in median (P = 0.004) and cumulative (P = 0.002) Neuroloopgain values of spindle, and median (P = 0.002) and cumulative (P = 0.002) power values of delta ( Figure 5 ), indicative of reduced spindle and delta genesis during SWS.
Discussion
This study comprehensively evaluated the distinct changes in sleep architecture brought about by Manasamitra Vataka with or without Shirodhara and clonazepam interventions in GAD patients with co-morbid generalized social phobia. Ayurvedic treatments were found to be more effective in promoting and preserving SWS thus maintaining the normal sleep architecture, whereas clonazepam treatment grossly altered the sleep architecture in GAD patients.
Insomnia is quite prevalent in GAD 17 and almost 60-70% patients with GAD reported sleep disturbances such as trouble falling and staying asleep, increased daytime fatigue, irritability and difficulty in coping 1, 3 . Patients with SP reported poor sleep quality, longer sleep latency, Data expressed as mean  SD. *P < 0.05, **P < 0.01, ***P < 0.001. NREM, Non-rapid eye movement sleep; REM, Rapid eye movement sleep, SOL, Sleep onset latency; ROL, REM onset latency; SWS, Slow wave sleep.
frequent awakenings and daytime dysfunctions 18 . In the present study, almost 56% of patients reported history of disturbed sleep, delayed period of sleep onset, more awakenings per night and non-refreshing type of sleep. Following treatment interventions, patients from all groups reported improvement in sleep quality and felt refreshed after sleep. Sleep architecture profiles revealed that the major sleep variables like sleep efficiency, duration, micro-arousals, etc. were almost within the normal physiological limits 19 . Some studies however revealed inconclusive reports; either increase or decrease in NREM S1, NREM S2, NREM S4, changes in NREM S3 and REM sleep, etc 4 . Differences observed in both subjective and objective sleep assessments could be associated with sleep disturbances in the patients. The SWS states are restorative in nature and Ayurvedic interventions preserved them. Additionally, Ayurvedic treatments (Manasamitra Vataka treatment with and without Shirodhara) reduced the NREM S1 sleep, thus reducing sleep onset latency, reduced intermittent awakenings, and helped maintain sleep continuity. Clonazepam treatment enhanced NREM S2, REM (%), REM onset latency but significantly reduced SWS, which is an important component of restoration. Benzodiazepine 20 has been shown to grossly alter Data expressed in mean  standard deviation.*P < 0.05, **P < 0.01, ***P < 0.001.
the sleep architecture 5 . Our study also demonstrated such non-restorative quality of sleep by clonazepam. The literature on the effects of clonazepam on sleep architecture is scanty and the present study contributes towards its role on sleep architecture.
Manasamitra Vataka is a compound formulation, which has nootropic, psychotropic and anxiolytic properties 9, 10 . Ingredients such as Withania somnifera have GABA-mimetic activity 21 ; Bacopa monneira has been shown to promote sleep 22 . Up-regulation of serotonin receptors 23 and GABAergic modulation of B. monniera 24 and Centella asiatica 25 have also been reported. However, the effect of external use of Brahmi oil (B. monnieri) has not been reported. Shirodhara treatment has been shown to produce anxiolytic effects as assessed by state-trait anxiety inventory [26] [27] [28] [29] and Shirodhara effect could be through brain-targeted transcranial drug delivery 30, 31 . The present study shows that Shirodhara with Brahmi oil considerably reduces the micro-arousals and helps in sleep continuity. We have earlier reported about the sleep-promoting effects of Shirodhara, as the treatment significantly reduces daytime sleepiness 10 . Moreover, the spindle-delta dynamics examined on a subgroup of patients, also showed no significant alteration after Ayurvedic treatment. On the contrary, clonazepam treatment resulted in deficits in delta power and spindle density (inferred from Neuroloopgain analysis), which are indications of reduced sleep intensity.
Ayurvedic treatments are thus more effective compared to clonazepam in maintaining a proper sleep architecture, spindle-delta dynamics, and also help in preserving SWS. Sleep spindles are believed to be a key player in sleep maintenance, particularly in the progression to deeper SWS and transition to REM sleep. SWS has a significant role in maintaining body homeostasis like cerebral restoration and recovery 32, 33 . SWS is the main time period for secretion of anabolic growth hormone 34 , for tissue repair and growth 35 , synaptic density 36 , learning and synaptic plasticity, memory consolidation, especially declarative memory 37 and is involved in the maintenance and consolidation of sleep 38 . The present study has several limitations as it is openlabelled and not a double-blind randomized control study. An additional placebo group would have helped demonstrate the subsequent changes in sleep after the interventions; but this had other ethical implications. Similarly, long-term interventions would have been more effective on the clinical and sleep profiles. As both Manasamitra Vataka and Shirodhara are being studied for the first time on a psychiatric population 10 , further studies are required to understand the profile of the medications on other biological parameters as well.
Overall, the study highlights the sleep promoting and preserving nature of Manasamitra Vataka and Shirodhara in GAD patients with co-morbid generalized SP. Ayurvedic treatments helped in improve the subjective quality of sleep and preserve sleep organization. They were also found to be highly effective over clonazepam in terms of preserving SWS and maintaining sleep quality. Shirodhara treatment had an add-on effect on Manasamitra Vataka treatment, as it helped improve the sleep continuity by reducing the micro-arousals and also the daytime sleepiness 10 . Clinical variables outcome showed that Ayurvedic interventions were effective in ameliorating GAD with co-morbid generalized SP and were comparable to clonazepam 10 . Hence Ayurvedic interventions like Manasamitra Vataka can be the drug of choice in the comprehensive management of GAD with generalized SP. The medications used in the present study are suggestive of an effective comprehensive treatment strategy in GAD with generalized SP.
